p53 and p73 display common and distinct requirements for sequence specific binding to DNA

Nucleic Acids Research

Volumn 35, Issue 1, 2007, Pages 340-352

  Lokshin, Maria ^b   Li, Yingchun ^b   Gaiddon, Christian ^a   Prives, Carol ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT; COPPER; EDETIC ACID; PROTEIN P21; PROTEIN P53; PROTEIN P73; PROTEIN P73 BETA; UNCLASSIFIED DRUG; ZINC;

ARTICLE; BACULOVIRUS; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHELATION; CONTROLLED STUDY; DNA BINDING; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE DELETION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; SEQUENCE HOMOLOGY; TRANSACTIVATION;

BASE SEQUENCE; BINDING SITES; CELL LINE; CHELATING AGENTS; CONSENSUS SEQUENCE; CYSTEINE; DNA; DNA-BINDING PROTEINS; EDETIC ACID; HUMANS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE DELETION; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; ZINC;

EID: 33846704798     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkl1047     Document Type: Article

References (74)

1. Levrero,M., De Laurenzi,V., Costanzo,A., Gong,J., Wang,J.Y. and Melino,G. (2000) The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci., 113, 1661-1670.
2. Moll,U.M., Erster,S. and Zaika,A. (2001) p53, p63 and p73 - solos, alliances and feuds among family members. Biochim. Biophys. Acta., 1552, 47-59.
3. Yang,A., Kaghad,M., Caput,D. and McKeon,F. (2002) On the shoulders of giants: P63, p73 and the rise of p53. Trends Genet., 18, 90-95.
4. Derry,W.B., Putzke,A.P. and Rothman,J.H. (2001) Caenorhabditis elegans p53: Role in apoptosis, meiosis, and stress resistance. Science, 294, 591-595.
5. Schumacher,B., Hofmann,K., Boulton,S. and Gartner,A. (2001) The C.elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis. Curr. Biol., 11, 1722-1727.
6. Mendoza,L., Orozco,E., Rodriguez,M.A., Garcia-Rivera,G., Sanchez,T., Garcia,E. and Gariglio,P. (2003) Ehp53, an Entamoeba histolytica protein, ancestor of the mammalian tumour suppressor p53. Microbiology, 149, 885-893.
7. Murray-Zmijewski,F., Lane,D.P. and Bourdon,J.C. (2006) p53/p63/p73 isoforms: An orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ., 13, 962-972.
8. Scoumanne,A., Harms,K.L. and Chen,X. (2005) Structural basis for gene activation by p53 family members. Cancer Biol. Ther., 4, 1178-1185.
9. Laptenko,O. and Prives,C. (2006) Transcriptional regulation by p53: One protein, many possibilities. Cell Death Differ., 13, 951-961.
10. el-Deiry,W.S., Kern,S.E., Pietenpol,J.A., Kinzler,K.W. and Vogelstein,B. (1992) Definition of a consensus binding site for p53. Nature Genet., 1, 45-49.
11. Halazonetis,T.D. and Kandil,A.N. (1993) Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J., 12, 5057-5064.
12. Prives,C. and Hall,P.A. (1999) The p53 pathway. J. Pathol., 187, 112-126.
13. McLure,K.G. and Lee,P.W. (1998) How p53 binds DNA as a tetramer. EMBO J., 17, 3342-3350.
14. Friedman,P.N., Chen,X., Bargonetti,J. and Prives,C. (1993) The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl Acad. Sci. USA, 90, 3319-3323.
15. Kitayner,M., Rozenberg,H., Kessler,N., Rabinovich,D., Shaulov,L., Haran,T.E. and Shakked,Z. (2006) Structural basis of DNA recognition by p53 tetramers. Mol. Cell, 22, 741-753.
16. Ho,W.C., Fitzgerald,M.X. and Marmorstein,R. (2006) Structure of the p53 Core Domain Dimer Bound to DNA. J. Biol. Chem., 281, 20494-20502.
17. Kim,E., Albrechtsen,N. and Deppert,W. (1997) DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. Oncogene, 15, 857-869.
18. Szak,S.T., Mays,D. and Pietenpol,J.A. (2001) Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol., 21, 3375-3386.
19. Kaeser,M.D. and Iggo,R.D. (2002) Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl Acad. Sci. USA, 99, 95-100.
20. Thornborrow,E.C. and Manfredi,J.J. (1999) One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. J. Biol. Chem., 274, 33747-33756.
21. Qian,H., Wang,T., Naumovski,L., Lopez,C.D. and Brachmann,R.K. (2002) Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding site. Oncogene, 21, 7901-7911.
22. Inga,A., Storici,F., Darden,T.A. and Resnick,M.A. (2002) Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol. Cell. Biol., 22, 8612-8625.
23. Hoh,J., Jin,S., Parrado,T., Edington,J., Levine,A.J. and Ott,J. (2002) The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl Acad. Sci. USA, 99, 8467-8472.
24. Wei,C.L., Wu,Q., Vega,V.B., Chiu,K.P., Ng,P., Zhang,T., Shahab,A., Yong,H.C., Fu,Y., Weng,Z. et al. (2006) A global map of p53 transcription-factor binding sites in the human genome. Cell, 124, 207-219.
25. Olivier,M., Eeles,R., Hollstein,M., Khan,M.A., Harris,C.C. and Hainaut,P. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat., 19, 607-614.
26. Cho,Y., Gorina,S., Jeffrey,P.D. and Pavletich,N.P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science, 265, 346-355.
27. Pavletich,N.P., Chambers,K.A. and Pabo,C.O. (1993) The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev., 7, 2556-2564.
28. Hainaut,P. and Milner,J. (1993) A structural role for metal ions in the 'wild-type' conformation of the tumor suppressor protein p53. Cancer Res., 53, 1739-1742.
29. Verhaegh,G.W., Parat,M.O., Richard,M.J. and Hainaut,P. (1998) Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. Mol. Carcinog., 21, 205-214.
30. Meplan,C., Richard,M.J. and Hainaut,P. (2000) Metalloregulation of the tumor suppressor protein p53: Zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene, 19, 5227-5236.
31. McKinney,K., Mattia,M., Gottifredi,V. and Prives,C. (2004) p53 linear diffusion along DNA requires its C terminus. Mol. Cell, 16, 413-424.
32. Espinosa,J.M. and Emerson,B.M. (2001) Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell, 8, 57-69.
33. Ahn,J. and Prives,C. (2001) The C-terminus of p53: The more you learn the less you know. Nature Struct. Biol., 8, 730-732.
34. Kaghad,M., Bonnet,H., Yang,A., Creancier,L., Biscan,J.C., Valent,A., Minty,A., Chalon,P., Lelias,J.M., Dumont,X. et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90, 809-819.
35. Jost,C.A., Marin,M.C. and Kaelin,W.G.,Jr (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature, 389, 191-194.
36. Irwin,M.S. and Kaelin,W.G. (2001) p53 family update: P73 and p63 develop their own identities. Cell Growth Differ., 12, 337-349.
37. Ozaki,T. and Nakagawara,A. (2005) p73, a sophisticated p53 family member in the cancer world. Cancer Sci., 96, 729-737.
38. Oberst,A., Rossi,W., Salomoni,P., Pandolfi,P.P., Oren,M., Melino,G. and Bernassola,F. (2005) Regulation of the p73 protein stability and degradation. Biochem. Biophys. Res. Commun., 331, 707-712.
39. Moll,U.M. and Slade,N. (2004) p63 and p73: Roles in development and tumor formation. Mol. Cancer Res., 2, 371-386.
40. Melino,G., Lu,X., Gasco,M., Crook,T. and Knight,R.A. (2003) Functional regulation of p73 and p63: Development and cancer. Trends Biochem. Sci., 28, 663-670.
41. Stiewe,T., Theseling,C.C. and Putzer,B.M. (2002) Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: Implications for tumorigenesis. J. Biol. Chem., 277, 14177-14185.
42. Nakagawa,T., Takahashi,M., Ozaki,T., Watanabe Ki,K., Todo,S., Mizuguchi,H., Hayakawa,T. and Nakagawara,A. (2002) Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol. Cell. Biol., 22, 2575-2585.
43. Grob,T.J., Novak,U., Maisse,C., Barcaroli,D., Luthi,A.U., Pirnia,F., Hugli,B., Graber,H.U., De Laurenzi,V., Fey,M.F. et al. (2001) Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ., 8, 1213-1223.
44. Liu,G., Nozell,S., Xiao,H. and Chen,X. (2004) DeltaNp73beta is active in transactivation and growth suppression. Mol. Cell. Biol., 24, 487-501.
45. Ozaki,T., Naka,M., Takada,N., Tada,M., Sakiyama,S. and Nakagawara,A. (1999) Deletion of the COOH-terminal region of p73alpha enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells. Cancer Res., 59, 5902-5907.
46. Chen,X. (1999) The p53 family: Same response, different signals? Mol. Med. Today, 5, 387-392.
47. Ueda,Y., Hijikata,M., Takagi,S., Chiba,T. and Shimotohno,K. (1999) New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene, 18, 4993-4998.
48. Alarcon-Vargas,D., Fuchs,S.Y., Deb,S. and Ronai,Z. (2000) p73 transcriptional activity increases upon cooperation between its spliced forms. Oncogene, 19, 831-835.
49. Arrowsmith,C.H. (1999) Structure and function in the p53 family. Cell Death Differ., 6, 1169-1173.
50. Zhu,J., Jiang,J., Zhou,W. and Chen,X. (1998) The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res., 58, 5061-5065.
51. Lee,C.W. and La Thangue,N.B. (1999) Promoter specificity and stability control of the p53-related protein p73. Oncogene, 18, 4171-4181.
52. Fontemaggi,G., Kela,I., Amariglio,N., Rechavi,G., Krishnamurthy,J., Strano,S., Sacchi,A., Givol,D. and Blandino,G. (2002) Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J. Biol. Chem., 277, 43359-43368.
53. Harms,K., Nozell,S. and Chen,X. (2004) The common and distinct target genes of the p53 family transcription factors. Cell. Mol. Life Sci., 61, 822-842.
54. Nozell,S., Wu,Y., McNaughton,K., Liu,G., Willis,A., Paik,J.C. and Chen,X. (2003) Characterization of p73 functional domains necessary for transactivation and growth suppression. Oncogene, 22, 4333-4347.
55. Urist,M., Tanaka,T., Poyurovsky,M.V. and Prives,C. (2004) p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev., 18, 3041-3054.
56. Jayaraman,L., Freulich,E. and Prives,C. (1997) Functional dissection of p53 tumor suppressor protein. Meth. Enzymol., 283, 245-256.
57. Arslan,P., Di Virgilio,F., Beltrame,M., Tsien,R.Y. and Pozzan,T. (1985) Cytosolic Ca2+ homeostasis in Ehrlich and Yoshida carcinomas. A new, membrane-permeant chelator of heavy metals reveals that these ascites tumor cell lines have normal cytosolic free Ca2?. J. Biol. Chem., 260, 2719-2727.
58. Stephen,C.W. and Lane,D.P. (1992) Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J. Mol. Biol., 225, 577-583.
59. Malpica,R., Franco,B., Rodriguez,C., Kwon,O. and Georgellis,D. (2004) Identification of a quinone-sensitive redox switch in the ArcB sensor kinase. Proc. Natl Acad. Sci. USA, 101, 13318-13323.
60. Wu,H.H., Thomas,J.A. and Momand,J. (2000) p53 protein oxidation in cultured cells in response to pyrrolidine dithiocarbamate: A novel method for relating the amount of p53 oxidation in vivo to the regulation of p53-responsive genes. Biochem. J., 351, 87-93.
61. Rainwater,R., Parks,D., Anderson,M.E., Tegtmeyer,P. and Mann,K. (1995) Role of cysteine residues in regulation of p53 function. Mol. Cell. Biol., 15, 3892-3903.
62. Freeman,J., Schmidt,S., Scharer,E. and Iggo,R. (1994) Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. EMBO J., 13, 5393-5400.
63. Zupnick,A. and Prives,C. (2006) Mutational analysis of the p53 core domain L1 loop. J. Biol. Chem., 281, 20464-20473.
64. Weinberg,R.L., Freund,S.M., Veprintsev,D.B., Bycroft,M. and Fersht,A.R. (2004) Regulation of DNA binding of p53 by its C-terminal domain. J. Mol. Biol., 342, 801-811.
65. Canadillas,J.M., Tidow,H., Freund,S.M., Rutherford,T.J., Ang,H.C. and Fersht,A.R. (2006) Solution structure of p53 core domain: Structural basis for its instability. Proc. Natl Acad. Sci. USA, 103, 2109-2114.
66. Nasulewicz,A., Mazur,A. and Opolski,A. (2004) Role of copper in tumour angiogenesis-clinical implications. J. Trace Elem. Med. Biol., 18, 1-8.
67. Mondal,N. and Parvin,J.D. (2005) The tumor suppressor protein p53 functions similarly to p63 and p73 in activating transcription in vitro. Cancer Biol. Ther., 4, 414-418.
68. Kartasheva,N.N., Contente,A., Lenz-Stoppler,C., Roth,J. and Dobbelstein,M. (2002) p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene, 21, 4715-4727.
69. Zeng,X., Lee,H., Zhang,Q. and Lu,H. (2001) p300 does not require its acetylase activity to stimulate p73 function. J. Biol. Chem., 276, 48-52.
70. Stros,M., Ozaki,T., Bacikova,A., Kageyama,H. and Nakagawara,A. (2002) HMGB1 and HMGB2 cell-specifically down-regulate the p53-and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J. Biol. Chem., 277, 7157-7164.
71. Osada,M., Park,H.L., Nagakawa,Y., Begum,S., Yamashita,K, Wu,G., Kim,M.S., Trink,B. and Sidransky,D. (2006) A novel response element confers p63- and p73-specific activation of the WNT4 promoter. Biochem. Biophys. Res. Commun., 339, 1120-1128.
72. Kaeser,M.D. and Iggo,R.D. (2004) Promoter-specific p53-dependent histone acetylation following DNA damage. Oncogene, 23, 4007-4013.
73. Campomenosi,P., Monti,P., Aprile,A., Abbondandolo,A., Frebourg,T., Gold,B., Crook,T., Inga,A., Resnick,M.A., Iggo,R. et al. (2001) p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene, 20, 3573-3579.
74. Nicholls,C.D., McLure,K.G., Shields,M.A. and Lee,P.W. (2002) Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J. Biol. Chem., 277, 12937-12945.